Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 in Metastatic Renal Cell Cancer
NCT00057889Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Feb 2003
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in renal cell carcinoma (RCC), sponsored by National Institutes of Health. Started Feb 2003; status: completed.
02
Drugs
ipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00057889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00057889.